New cocktail aims to shrink Hard-to-Treat stomach tumors
NCT ID NCT06939452
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial is testing a combination of three drugs—anlotinib, TQB2450, and the SOX chemotherapy regimen—as a first treatment for advanced stomach or gastroesophageal junction cancer that has low PD-L1 expression. The study involves 37 participants and aims to see how well the combo shrinks tumors and controls the disease. It is currently active but no longer recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
anlotinib (a drug that blocks blood vessel growth to tumors), TQB2450 (an immunotherapy drug), and the SOX chemotherapy regimen (oxaliplatin and S-1)
What this could lead to
If successful, this combination could offer a new first-line treatment option for people with advanced gastric cancer that has low PD-L1 expression, potentially improving tumor shrinkage and delaying disease progression.
What could go wrong
This is a small, early-phase (phase 2) trial with only 37 participants and no comparison group, so results may not apply broadly. The combination also carries risks of side effects from chemotherapy, immunotherapy, and the anti-angiogenic drug.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED GASTRIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New drug cocktail aims to tackle Hard-to-Treat stomach cancer
- New drug duo takes aim at hard-to-treat stomach cancer with liver metastases
- New pill combo aims to fight stomach cancer when first treatment fails
- Engineered immune cells take on stomach cancer in early trial
- Stomach cancer hope: new combo targets tumors after PD-1 failure
- Glowing dye may guide surgeons during stomach cancer operations